Twist Bioscience Corporation (NASDAQ:TWST – Get Free Report) CEO Emily Leproust sold 1,704 shares of the stock in a transaction that occurred on Monday, September 22nd. The stock was sold at an average price of $27.56, for a total transaction of $46,962.24. Following the sale, the chief executive officer directly owned 633,036 shares of the company’s stock, valued at approximately $17,446,472.16. This trade represents a 0.27% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.
Twist Bioscience Trading Up 0.6%
Shares of TWST stock opened at $26.91 on Friday. Twist Bioscience Corporation has a fifty-two week low of $24.07 and a fifty-two week high of $55.33. The firm’s 50 day moving average price is $28.55 and its two-hundred day moving average price is $33.43. The stock has a market cap of $1.62 billion, a price-to-earnings ratio of -18.56 and a beta of 2.31. The company has a quick ratio of 3.60, a current ratio of 3.90 and a debt-to-equity ratio of 0.03.
Twist Bioscience (NASDAQ:TWST – Get Free Report) last announced its quarterly earnings results on Monday, August 4th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.54) by $0.07. Twist Bioscience had a negative return on equity of 29.03% and a negative net margin of 23.51%.The firm had revenue of $96.06 million during the quarter, compared to the consensus estimate of $95.52 million. Twist Bioscience has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. On average, analysts anticipate that Twist Bioscience Corporation will post -2.12 EPS for the current year.
Analyst Ratings Changes
Get Our Latest Research Report on TWST
Hedge Funds Weigh In On Twist Bioscience
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Versant Capital Management Inc boosted its position in Twist Bioscience by 547.2% during the 1st quarter. Versant Capital Management Inc now owns 686 shares of the company’s stock valued at $27,000 after purchasing an additional 580 shares during the period. GAMMA Investing LLC boosted its stake in Twist Bioscience by 68.1% during the 1st quarter. GAMMA Investing LLC now owns 748 shares of the company’s stock valued at $29,000 after purchasing an additional 303 shares during the period. GF Fund Management CO. LTD. acquired a new position in Twist Bioscience during the 4th quarter valued at about $58,000. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Twist Bioscience by 15.0% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,315 shares of the company’s stock worth $85,000 after buying an additional 302 shares during the period. Finally, Geneos Wealth Management Inc. acquired a new position in shares of Twist Bioscience during the second quarter worth approximately $97,000.
About Twist Bioscience
Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.
Featured Articles
- Five stocks we like better than Twist Bioscience
- What does consumer price index measure?
- Pfizer is Locking in New Growth Through a New Acquisition
- What Are the U.K. Market Holidays? How to Invest and Trade
- Copper Giant Freeport Slumps but Analysts See 33% Upside
- Options Trading – Understanding Strike Price
- The BYD Opportunity: Tesla-Like Growth at a Fraction of the Price
Receive News & Ratings for Twist Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Twist Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.